Oral ibandronic acid versus intravenous zoledronic acid in treatment of bone metastases from breast cancer: a randomised, open label, non-inferiority phase 3 trial

Peter Barrett‐Lee, Nick Murray, Duncan Wheatley et al.|The Lancet Oncology|2013

Cited by 128